AHA Scientific Sessions 2026 Abstract · Nov 2, 2026

Association of Fibrosis-4 Scores as a Time Varying Covariate with Cardiovascular Disease Outcomes: A Retrospective Cohort Study in A National Cohort of Primary Care Patients

By Senthil S

Background: Metabolic dysfunction-associated steatotic liver disease, a manifestation of the metabolic syndrome affects around 38% of Americans. It is associated with a higher risk for cardiovascular disease (CVD) events-i.e., acute myocardial infarction (AMI), congestive heart failure (CHF), and ischemic stroke. Fibrosis-4 Index (FIB-4) is calculated using aminotransferases [aspartate (AST) and alanine (ALT)], and platelets [FIB-4 =(Age x AST)/(Platelets x √ALT). It assesses advanced fibrosis risk in patients with chronic liver disease. FIB-4 has been shown to have an association with CVD events but is not utilized as a predictor of CVD outcomes in clinical practice. We wanted to understand the additional predictive information of FIB-4 beyond traditional CVD risk indicators and how this association varies over time, while controlling for cardiometabolic therapies like statins, insulin, metformin, glucagon like peptide 1 receptor agonists (GLP-1a). Methods: This is a retrospective cohort study of electronic health record data from a national cohort of Veterans, extracted from the VA Corporate Data Warehouse. Veterans with calculable FIB-4 scores from January 2011 to December 2025 were identified, and excluded if CVD event occurred before 2011. FIB-4 scores were categorized as low (FIB-4 <1.3), indeterminate (1.3 ≤ FIB-4 <2.67), or high-risk (FIB-4 ≥ 2.67) for advanced fibrosis. We used multivariable complementary log-log (cloglog) regression models to evaluate the association between FIB-4 scores and other potential confounders and covariates with time to composite CVD event outcome (AMI, CHF, and stroke). Results: A total of 2,431,410 unique patients were identified. Approximately 45% of patients were 64 years of age or older, male (93.5%), and White (73.9%). Among this cohort, 43% had diabetes mellitus, 24% had chronic kidney disease (CKD), and 24.2% had severe liver disease (SLD). During a mean follow-up of 10.23 years, patients with FIB-4 scores at high- (HR=1.26; 95% CI [1.25 - 1.27]) or indeterminate-risk (HR=1.26; 95% CI [1.09 - 1.1.09 - 1.10]) for advanced fibrosis were more likely to experience a CVD event compared to those with low-risk FIB-4 scores. Other factors associated with an elevated hazard for CVD events included CKD (HR=1.58; 95%CI [1.57 - 1.59]), SLD (HR=1.31; 95%CI [1.30 - 1.33]), prescription for insulin (HR=1.94; 95% CI [1.93 - 1.96]) and statin (HR=2.02; 95% CI [2.01 - 2.03]). Alternatively, a prescription for GLP-1a and metformin had an associated 19% (HR=0.81; 95% CI [1.93 - 1.96]) and 12% (HR=0.88; 95%CI [0.87 - 0.89]) reduction of CVD event hazard, respectively. Conclusions: In a large cohort of Veterans from primary care, FIB-4 scores at high- and indeterminate-risk for advanced fibrosis were associated with an increased risk of incident CVD over time. The utility of adding FIB-4 components to future CVD risk prognostication requires further exploration.

doi.org/10.1161/circ.154.suppl_1.13429Biomarkers

AgingResearch.News